Liposomal Ocular Drug Delivery System Development Service

Introduction to Our Liposomal Ocular Drug Delivery System Development Service

Advancing ocular drug delivery systems remains a complex necessity in modern medical treatments. To deliver drugs to the eye successfully healthcare professionals must navigate biological obstacles like the corneal epithelium and the blood-retina barrier. The liposomal ocular drug delivery system stands out as a top solution because it provides better bioavailability while ensuring sustained drug release and precise targeting. As a biochemical services leader, BOC Sciences supports your ocular drug development using advanced liposome-based formulations . We provide specialized services designed to support the preclinical research efforts of scientists and drug companies developing new eye treatment therapies.

How to Get Started with Us?

  • Reach out to us by submitting an inquiry via our website or directly through email to initiate a discussion about your liposomal ocular drug delivery project.
  • Schedule a consultation with our experts to define the project's scope, objectives, and specific needs for your ocular drug delivery system.
  • Our team will assess your project's technical feasibility and provide preliminary insights, guiding you toward the best approach for liposomal formulation development.
  • Receive a tailored development plan, including a clear timeline, detailed budget, and key milestones for your project.
  • Finalize the partnership by reviewing and signing a formal agreement, after which the development process will officially begin.

Inquire today to accelerate your vaccine development.

Request A Quote

Contact us to discuss how we can help you achieve your research goals

Price Inquiry

Barriers of Ocular Drug Delivery System

The ocular drug delivery system faces several barriers that hinder efficient drug absorption and bioavailability. These include the physical and anatomical barriers like the corneal epithelium, conjunctiva, and blood-retinal barrier, as well as the ocular surface's natural protective mechanisms such as tear drainage and blinking. The small surface area of the cornea and the rapid turnover of tears also limit drug retention, making it challenging to achieve therapeutic drug concentrations in the eye. Additionally, the lipophilic nature of many ocular tissues complicates the penetration of hydrophilic drugs.

Why Choose Liposomes for Ocular Drug Delivery?

1. Enhanced Corneal Permeation and Retention: Liposomes can fuse with corneal epithelial cell membranes due to their phospholipid bilayer structure, enhancing transcorneal penetration. Studies demonstrate up to 3–5x increased corneal absorption with liposomal carriers versus traditional formulations.
2. Prolonged Drug Residence Time: Cationic or mucoadhesive liposomes can interact with negatively charged mucins in the tear film, extending precorneal residence time and reducing dosing frequency—critical for chronic diseases like glaucoma or uveitis.
3. Reduced Systemic Absorption: By localizing the drug at the site of action, liposomes minimize systemic spillover and adverse effects. This is particularly vital for corticosteroids and immunosuppressants used in ocular disorders.
4. Targeted Delivery to Anterior and Posterior Segments: PEGylated or ligand-functionalized liposomes offer targeted drug release to specific ocular tissues, such as the retina, choroid, and ciliary body, facilitating treatment of diseases like age-related macular degeneration and diabetic retinopathy.

The use of liposomes in ocular drug delivery. (BOC Sciences Original)Schematic diagram of the liposomes for ocular drug delivery. (BOC Sciences Original)

Comprehensive Services for Liposomal Ocular Drug Delivery System Development

At BOC Sciences, we provide a comprehensive suite of specialized services to support the development of liposomal ocular drug delivery systems. Our expertise spans from formulation to characterization, testing, and optimization, ensuring that your liposomal systems are ideal for ocular applications. We understand the unique challenges presented by ocular drug delivery, and as such, we offer targeted solutions that align with the specific requirements of the eye's anatomy and therapeutic needs.

Specialized Lipid Raw Materials for Ocular Drug Delivery

The selection of lipid materials is a critical component in the design of liposomal ocular drug delivery systems. At BOC Sciences, we offer a wide range of lipids specifically suited for ocular formulations, taking into account factors such as biocompatibility, stability, and permeability to optimize drug delivery to ocular tissues.

  • Phosphatidylcholine (PC) & Phosphatidylethanolamine (PE): These phospholipids form the basic structure of liposomes, promoting cellular uptake in ocular tissues and stability.
  • Cholesterol: Added to enhance liposomal bilayer stability and prevent premature drug leakage, ensuring controlled release in ocular applications.
  • PEGylated Lipids: For improved retention on the ocular surface and longer circulation time, we provide PEGylated lipids that help avoid rapid clearance from the eye.
  • Eye-Specific Lipid Combinations: We offer tailored lipid combinations designed to improve ocular surface retention, minimize irritation, and maximize drug absorption. These combinations include lipids like dimyristoylphosphatidylcholine (DMPC) and distearoylphosphatidylcholine (DSPC), which are well-suited for extended ocular drug release.

Custom Liposomal for Ocular Drug Delivery

Different liposomal formulations may be required depending on the drug's nature and the therapeutic goal. We offer several types of liposomes optimized for ocular delivery:

  • Conventional Liposomes: Simple bilayer vesicles suitable for hydrophilic or amphiphilic drugs, ideal for conditions requiring rapid drug release.
  • Stealth Liposomes: Modified with PEG to enhance circulation time and promote sustained drug release for chronic conditions like AMD or glaucoma.
  • Targeted Liposomes: Surface-modified with specific ligands (e.g., antibodies, peptides) to target ocular tissues, such as the retina, providing precise drug delivery.
  • Multilamellar Vesicles (MLVs): For higher drug payloads and controlled release, MLVs are suitable for hydrophilic and hydrophobic drugs that require prolonged ocular delivery.
  • Nanoliposomes: Small unilamellar vesicles for effective penetration of the corneal epithelium, particularly for hydrophilic drugs targeting deeper ocular layers.

Types of Ocular Drugs Supported by Liposomal Delivery

Liposomes can effectively deliver a range of drugs, both hydrophilic and hydrophobic, to the eye. We provide liposome-based encapsulation for:

Advantages of Synbiotic Co-Encapsulation:

  • Hydrophilic Drugs: Suitable for corticosteroids, NSAIDs, and antibiotics, enhancing their stability and reducing irritation while improving ocular penetration.
  • Hydrophobic Drugs: Ideal for anti-cancer agents or antiviral medications, liposomes help deliver hydrophobic drugs directly to ocular tissues, minimizing systemic exposure.
  • Gene Therapy and Biologics: Liposomal formulations are well-suited for delivering gene therapies, RNA-based therapeutics, and monoclonal antibodies to ocular tissues, protecting sensitive compounds from degradation.
  • Anti-VEGF Agents: Liposomal formulations of anti-VEGF drugs provide sustained release, reducing the need for frequent injections in diseases like wet AMD.

Tailored Ocular Drug Release Profiles

We offer customized release profiles to meet the therapeutic needs of ocular conditions:

  • Extended Release: Our liposomal formulations can provide sustained drug release, ideal for chronic conditions like glaucoma or retinal diseases.
  • Burst Release: For conditions requiring rapid action, such as acute ocular inflammation or infection, liposomes can be designed for fast drug release.
  • pH-Responsive Release Liposome: Incorporating pH-sensitive lipids allows for drug release upon contact with the slightly acidic ocular environment, ensuring precise and controlled delivery.

Ocular Drug In Vitro and In Vivo Testing Services

At BOC Sciences, we offer a comprehensive range of in vitro and in vivo testing services tailored to evaluate the performance, efficacy, and safety of liposomal ocular drug delivery systems.

(1) Our in vitro testing models replicate the ocular environment to assess essential characteristics of liposomal formulations. These include:

  • Corneal Permeability Models: Used to evaluate how effectively the liposomal formulation can penetrate the ocular surface.
  • Human Ocular Cell Cultures: These cell-based assays help assess the biocompatibility and toxicity of liposomal formulations on human-derived ocular cells.
  • Ex Vivo Ocular Tissue Models: Isolated eye tissues are used to simulate drug release and distribution, providing more accurate predictions of ocular drug behavior.

(2) In vivo testing allows for the evaluation of pharmacokinetics, biodistribution, and therapeutic efficacy of liposomal ocular formulations in animal models. Our services include:

  • Pharmacokinetics and Biodistribution Studies: We assess how the drug is absorbed, distributed, and retained in ocular tissues in animal models, helping to predict the drug's performance in humans.
  • Efficacy Studies: These studies evaluate the therapeutic effects of liposomal ocular formulations in disease models like dry eye, retinal degeneration, and glaucoma.
  • Toxicity and Safety Assessment: In vivo safety studies identify potential adverse effects of liposomal formulations, ensuring that they are safe for long-term use in ocular applications.

Step-by-Step Process of Liposomal Ocular Drug Delivery System Development

At BOC Sciences, we employ a structured and thorough approach to develop liposomal ocular drug delivery systems, ensuring that every step is optimized for efficacy, safety, and targeted drug delivery.

1. Initial Consultation and Drug Characterization

We begin by understanding your drug formulation and therapeutic needs. This includes assessing its physicochemical properties, solubility, stability, and ocular compatibility to determine the ideal liposomal delivery system.

  • Drug Properties Assessment: Understanding hydrophobicity, size, molecular weight, and stability.
  • Ocular Compatibility Evaluation: Ensuring minimal irritation and optimal delivery.

2. Selection of Liposomal Formulation

Based on the drug's characteristics, we select the appropriate lipid materials and liposome type (e.g., conventional, stealth, or targeted) to ensure efficient ocular delivery.

  • Lipid Selection: Choosing phospholipids, cholesterol, and other components for stability and encapsulation.
  • Liposomal Type Decision: Selecting the right liposome for targeted release and effective ocular penetration.

3. Custom Liposomes and Optimization

We prepare and optimize the liposomal formulation, focusing on achieving maximum drug encapsulation efficiency and stability while fine-tuning particle size for effective ocular absorption.

4. In-Vitro & Vivo Testing and Evaluation

After formulation, we conduct in-vitro tests to evaluate drug release, stability, and ocular compatibility. These tests simulate ocular conditions to predict how the liposomal formulation will perform.

  • Drug Release Studies: Monitoring drug release in simulated tear fluid.
  • Stability and Toxicity Testing: Ensuring formulation stability and biocompatibility with ocular tissues.

5. Preclinical Testing and Pharmacokinetic Studies

We perform preclinical pharmacokinetic studies in animal models to assess ocular absorption, tissue distribution, and retention, which informs optimization efforts.

  • Ocular Distribution Studies: Tracking the drug's behavior in ocular tissues.
  • Retention and Bioavailability: Evaluating how long the drug stays in the eye and its effectiveness.

6. Optimization of Drug Release and Efficacy

Based on in-vitro and preclinical results, we optimize the formulation to enhance drug release profiles, ensuring sustained or burst release based on the therapeutic requirement.

  • Release Profile Adjustment: Tuning release rates for controlled or rapid release.
  • Formulation Refinement: Adjusting parameters like pH sensitivity and surface charge.

7. Final Evaluation and Client Feedback

Once the formulation reaches its final version, we review it with you, integrating your feedback to ensure the system meets your specifications before progressing further.

  • Formulation Review: Ensuring consistency and performance.
  • Client Feedback Integration: Final adjustments based on your requirements.

Benefits of Our Liposomal Ocular Drug Delivery System Development Service

Applications of Our Liposomal Ocular Drug Delivery System Development Service

Liposomes have emerged as a powerful tool for targeted ocular drug delivery, offering a wide range of applications across various eye diseases. By utilizing liposomal carriers, BOC Sciences ensures efficient drug delivery with enhanced therapeutic efficacy and minimized side effects.

Glaucoma Therapy

  • Targeted Drug Delivery: Liposomal systems, with their ability to release drugs over extended periods, can effectively deliver prostaglandin analogs, beta-blockers, or rho kinase inhibitors directly to the ocular surface. This ensures sustained pressure reduction without the need for frequent redosing.
  • Enhanced Bioavailability: The liposomes' phospholipid bilayer enhances penetration across the corneal barrier, ensuring deeper drug delivery to intraocular tissues.

Uveitis and Inflammatory Eye Diseases

Uveitis and other ocular inflammatory diseases involve the inflammation of the uveal tract and surrounding tissues, often requiring aggressive treatment with corticosteroids or immunosuppressants. However, these therapies often have systemic side effects, especially with long-term use.

  • Localized Treatment: Liposomes can encapsulate anti-inflammatory agents such as corticosteroids, methotrexate, or cyclosporine, providing targeted delivery to the inflamed ocular tissues, minimizing systemic exposure and side effects.
  • Prolonged Drug Action: By utilizing liposomal formulations with slow release profiles, drugs can be delivered to the eye over extended periods, providing continuous therapeutic effects and reducing the need for frequent administration.

Ocular Infections (Bacterial, Fungal, Viral)

Ocular infections, including keratitis, endophthalmitis, and other microbial infections of the eye, can be difficult to treat due to poor penetration of topical antibiotics and antifungals. Liposomal formulations enhance drug stability and efficacy in ocular tissues.

  • Enhanced Ocular Penetration: Liposomes facilitate the penetration of antibiotics, such as ciprofloxacin, or antifungals like amphotericin B, into the cornea and other ocular tissues, which are often difficult to reach with conventional therapies.
  • Targeted Delivery to Site of Infection: Liposomal carriers can be engineered to deliver high concentrations of drugs directly to the site of infection, improving therapeutic outcomes and reducing the risk of drug resistance.

Retinal Disorders

Retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa, are often treated with intravitreal injections. However, these treatments are invasive and require frequent administration. Liposomal formulations offer a less invasive, more sustainable approach to delivering therapeutics to the retina.

  • Intravitreal Delivery: Liposomal systems can encapsulate biologics such as anti-VEGF antibodies or neuroprotective agents, ensuring precise and controlled release directly to the retina and choroid.
  • Prolonged Release for Retinal Diseases: By extending drug release over weeks or months, liposomes reduce the need for frequent injections, improving patient comfort and compliance. This approach is particularly valuable for treating chronic retinal diseases.

Ocular Gene Delivery and RNA Therapeutics

Gene and RNA-based therapies are revolutionizing the treatment of genetic ocular diseases such as Leber congenital amaurosis (LCA) and retinal dystrophies. Liposomal systems are ideal for the safe and effective delivery of nucleic acids to ocular tissues, bypassing the need for viral vectors and associated risks.

  • Safe and Efficient Delivery: Liposomes can encapsulate siRNA, mRNA, or plasmid DNA, providing a non-viral, biocompatible alternative for gene delivery to the eye. Liposomes can also be functionalized to enhance cellular uptake and targeted delivery to retinal cells.
  • Sustained Expression: Liposomal carriers provide controlled release of genetic material, which is crucial for sustained therapeutic effects in gene therapy applications, particularly in retinal gene editing or gene augmentation therapies.

FAQs – Insights about Our Liposomal Ocular Drug Delivery System Development Service

Product

What types of drugs are suitable for liposomal ocular delivery?

Both hydrophilic (e.g., peptides, small molecules) and hydrophobic (e.g., corticosteroids, NSAIDs) drugs can be encapsulated. Liposomes are also adaptable to macromolecules like nucleic acids.

Can you customize liposomal size and surface charge for different ocular compartments?

Absolutely. Our team applies precise control over liposome size (typically ranging from 50 nm to 200 nm) and zeta potential to optimize corneal penetration, prolong precorneal retention, or enhance posterior segment delivery. These parameters are critical for tissue-specific targeting in ocular pharmacokinetics.

Can you assist with liposomal encapsulation of poorly soluble ophthalmic drugs?

Certainly. One of the most compelling advantages of liposomes in ocular drug delivery is their ability to encapsulate poorly water-soluble molecules. Our team applies advanced techniques such as ethanol injection, reverse-phase evaporation, and active loading to maximize encapsulation efficiency and bioavailability of lipophobes.

What preclinical models do you support for evaluating ocular liposomal delivery systems?

Although BOC Sciences does not provide in vivo services, we offer comprehensive in vitro and ex vivo model support, including corneal permeation assays, transcorneal flux studies, and ex vivo porcine/bovine eye models. These tools allow predictive screening of liposomal formulations before advancing to third-party in vivo testing.

Can you co-encapsulate multiple therapeutic agents in a single liposomal formulation?

Yes. We are fully capable of co-loading hydrophilic and lipophilic drugs within a single liposomal system, enabling combination therapy approaches (e.g., anti-inflammatory + anti-infective agents) for complex ocular diseases such as uveitis or post-surgical inflammation.

Can you develop sustained-release liposomal systems for prolonged intraocular residence?

Yes. BOC Sciences has extensive experience in formulating sustained-release liposomal systems using strategies such as cholesterol modulation, polymer-coated liposomes, and hybrid lipid-polymer carriers to prolong drug action and reduce dosing frequency.

For scientifically engineered, highly customizable liposomal systems tailored to the unique demands of ocular pharmacology, partner with BOC Sciences. Our integrated approach ensures formulation success, from concept to preclinical readiness.

Supplementary Knowledges: Ocular Drug Delivery

Ocular drug delivery definition

Ocular drug delivery refers to the methods and technologies used to administer therapeutic agents directly to the eye for treating ocular diseases or conditions. This can involve a range of techniques, including topical, systemic, and implantable delivery methods, aimed at overcoming the physiological barriers of the eye to achieve effective drug concentrations in the targeted ocular tissue. The goal is to maximize drug efficacy while minimizing systemic side effects.

What are the ocular drug routes?

The main ocular drug routes are topical (direct application to the eye surface), systemic (oral or intravenous administration, which reaches the eye via blood circulation), intravitreal (injection directly into the vitreous humor), and subconjunctival (injection beneath the conjunctiva). Topical application is the most common method for surface eye diseases, while intravitreal injections are often used for treating retinal conditions like macular degeneration.

What is the ocular drug delivery method?

Ocular drug delivery methods include topical formulations (eye drops, gels, ointments), implantable systems (sustained-release devices or intraocular implants), injectable formulations (subconjunctival, intravitreal), and liposomal or nanoparticle-based carriers that enhance drug penetration and retention. These methods aim to overcome the anatomical and physiological barriers of the eye, ensuring that the drug reaches the desired ocular tissues for effective treatment.

Your Liposome CDMO Partner, Empowering Innovative Drug Development.

Contact Us

USA
  • International :
    US & Canada (Toll free):
  • Fax:
  • Email:

Europe

  • Tel:
  • Email:

Products

Solutions

Copyright ©  2025  BOC Sciences. All rights reserved.

Inquiry Basket
Loading ......
Delete selected Go to checkout